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Choi DE, Jeong JY, Lim BJ, Chung S, Chang YK, Lee SJ, Na
KR, Kim SY, Shin YT, Lee KW. Pretreatment of sildenafil attenu-
ates ischemia-reperfusion renal injury in rats. Am J Physiol Renal
Physiol 297: F362–F370, 2009. First published May 27, 2009;
doi:10.1152/ajprenal.90609.2008.—Sildenafil was the first selective
inhibitor of phosphodiesterase-5 (PDE5) to be widely used for treating
erectile dysfunction. Many recent studies have investigated the car-
dioprotective role of sildenafil in animal models. We evaluated the
protective effects of sildenafil in experimental renal ischemia-reper-
fusion (IR) injury in two studies. In study 1, male Sprague-Dawley
rats were divided into four groups: sham, sildenafil-treated sham,
vehicle-treated IR, and sildenafil-treated IR groups. In study 2, we
divided the rats into two groups: sildenafil-treated IR rats and
PD98059 (ERK inhibitor)sildenafil-treated IR rats. Functional pa-
rameters of the kidney were evaluated at the molecular and structural
levels. Blood urea nitrogen (BUN) and serum creatinine levels were
lower in sildenafil-treated IR rats than in vehicle-treated IR rats. The
expression of inducible (iNOS) and endothelial nitric oxide synthase
(eNOS) proteins in sildenafil-treated IR rats was significantly higher
than in vehicle-treated IR rats. Pretreatment with sildenafil in IR rats
increased ERK phosphorylation and reduced the renal Bax/Bcl-2
ratio, renal caspase-3 activity, and terminal dUTP nick end-labeling-
positive apoptotic cells. In contrast, PD98059 treatment increased
BUN and serum creatinine levels and attenuated the sildenafil-induced
expression of pERK, iNOS, eNOS, and Bcl-2. PD98059 also in-
creased caspase-3 activity but did not decrease the sildenafil-induced
accumulation of cGMP. In conclusion, this study suggests that silde-
nafil has antiapoptotic effects in experimental IR renal injury via ERK
phosphorylation, induction of iNOS and eNOS production, and a
decrease in the Bax/Bcl-2 ratio.
apoptosis; ERK
RENAL ISCHEMIA, WHETHER CAUSED by shock or during surgery or
transplantation, is a major cause of acute kidney injury. Al-
though reperfusion is essential for the survival of ischemic
tissue, there is good evidence that reperfusion itself causes
additional cellular injury. Renal ischemia-reperfusion (IR) in-
jury is caused by multiple insults involving tubular cell apop-
tosis, oxygen free radical formation, mitochondrial dysfunc-
tion, inflammatory cytokine generation, and neutrophil seques-
tration (22, 25, 26). It is important to improve the ability of
organs to tolerate ischemic injury, and the effects of IR injury
in kidney transplantation have been studied (7, 15). IR injury is
closely associated with increased acute rejection and late allo-
graft failure (39). Nitrogen oxide (NO) is an important medi-
ator of the physiological and pathological processes in renal IR
injury (26, 27, 46). Endogenous NO is synthesized by different
nitric oxide synthase (NOS) isoforms, which have been cloned
and characterized: endothelial NOS (eNOS), neuronal NOS
(nNOS), and inducible NOS (iNOS). Renal reperfusion follow-
ing ischemia activates NOS, and increases the expression of
NOS proteins (5, 29, 36). Despite these findings, the role of NO
in IR injury of the kidney remains controversial. Some have
reported that NO induces cellular cytotoxicity and tissue injury
via lipid peroxidation, DNA damage, and proapoptotic effects,
which are part of IR injury (4, 16, 17). However, many studies
have demonstrated that increased NOS activity is associated
with reduced IR injury and increased blood flow in the ische-
mic region (37). Nonselective NOS inhibitors such as NG-
nitro-L-arginine methyl ester worsen the postischemic renal
function, whereas L-arginine (a NO precursor) can reverse the
NOS inhibitor-induced deterioration of renal function (6).
Sildenafil citrate inhibits phosphodiesterase-5 (PDE5), which
catalyzes the breakdown of cGMP, one of the primary factors
involved in smooth muscle relaxation. Sildenafil induces the
upregulation of eNOS and iNOS, which generate NO (35). NO
activates guanylate cyclase, resulting in enhanced formation of
cGMP, which activates PKG. Subsequently, PKG opens the
mitochondrial KATP channels conferring cardioprotective ef-
fects against IR injury (24).
Sildenafil is used to treat erectile dysfunction in men (2).
Several recent studies have shown that sildenafil also offers
benefits in pulmonary arterial hypertension and congestive
heart failure (1, 20, 28).
In addition, sildenafil can improve the neurological outcome
and reduce neurological injury after transient spinal cord IR
following clamping of the thoracic aorta (23). Moreover, sil-
denafil provided cardioprotection against ischemia when in-
fused at the onset of reperfusion in rabbits (8). Sildenafil also
attenuated cardiomyocyte apoptosis in a chronic model of
doxorubicin cardiotoxicity and reduced the hypertrophic re-
sponse to isoprenaline in the mouse heart (14). Apoptosis is
also induced by renal IR injury associated with MAPK activa-
tion, Bax, Bcl-2, and caspase (33, 34), and sildenafil increased
ERK phosphorylation and the Bcl-2/Bax ratio in the heart (10,
11, 24).
Studies have shown that the inhibition of phosphodiesterase
decreases the renal injury. Guan et al. (19) showed that treat-
ment with zaprinast, a cGMP-specific phosphodiesterase inhib-
itor, 24 h after 60 min of bilateral renal artery clamping in the
rat, accelerated renal recovery by improving regional renal
blood flow. Early treatment with sildenafil ameliorated the
progression of renal damage in a 5⁄6 nephrectomy model (32).
Based on the tissue-protective effects of sildenafil, we hy-
pothesized that sildenafil would attenuate renal IR injury. Thus
we studied the protective mechanism involved in sildenafil
pretreatment.
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MATERIALS AND METHODS
Animals and Drug Treatment
All experiments were performed using 8-wk-old male Sprague-
Dawley (SD) rats (Samtako, Kyoung Gi-Do, Korea), weighing
250260 g. The rats were fed a standard laboratory diet and cared for
using a protocol approved by the Institutional Animal Care and Use
Committee of Chungnam National University Medical School. We
performed two studies. In study 1, we divided the rats into four
groups: sham-operated rats (S group), sildenafil-treated sham-oper-
ated rats (S-Sild group), vehicle-treated IR rats (IR group), and
sildenafil-treated IR rats (IR-Sild group). IR rats were killed at 1, 2, 4,
or 24 h after reperfusion of the left ischemic kidney. Sham and
sildenafil-treated sham-operated rats were killed at 1.58, 2.58, 4.58, or
24.58 h after the abdominal incision for the sham surgery. Kidneys
were prepared for Western blotting, real-time RT PCR, and histology.
Blood urea nitrogen (BUN) and serum creatinine levels were deter-
mined at 0, 4, 24, 48, 72, 120, and 168 h after reperfusion of the left
ischemic kidney in IR rats, and at 0.58, 1.58, 2.58, 4.58, and 24.58 h
after surgery in the sham and sildenafil-treated sham-operated rats
(Fig. 1). In study 2, we divided the rats into two groups: sildenafil-
treated IR rats and PD98059sildenafil-treated IR rats. The animals
were killed at 24 h after reperfusion of the left ischemic kidney. BUN
and serum creatinine levels were determined at 24 h after reperfusion
of the left ischemic kidney (Fig. 1). Kidneys were prepared for
Western blotting, real-time RT PCR, and histology.
The IR injury involved clamping of the left renal artery and vein for
35 min after nephrectomy of the right kidney. Sildenafil pretreatment
consisted of 0.5 mg/kg sildenafil (Viagra; Pfizer Australia, West Ryde,
NSW, Australia), administered once intraperitoneally 1 h before
ischemia of the left kidney. The vehicle (0.9% NaCl) was adminis-
tered in the same manner and volume. PD98059 (1 mg/kg; InSolution
PD98059; Calbiochem) pretreatment was administered once intrave-
nously at 0.5 h before ischemia of the left kidney. The rats were
anesthetized with a mixture of ketamine (50 mg/ml, 10 mg/kg;
Ketalar; Bayer, Leverkusen, Germany) and xylazine (2%, 0.1 ml/kg;
Rompun, Bayer) in solution (2 ml/kg) given intraperitoneally.
Tissue Preparation
After the rats were anesthetized, the left kidneys were excised
immediately and cut into three coronal sections. Two pieces of kidney
were snap-frozen in liquid nitrogen and kept at 70°C for subsequent
RNA extraction and protein analysis; the other piece was fixed in 10%
buffered formaldehyde at room temperature, and then embedded in
Paraplast (Sherwood Medical, St. Louis, MO) for light microscopy
and terminal dUTP nick end-labeling (TUNEL).
Light Microscopic Examination
Pieces of kidney embedded in Paraplast were cut into 4-m
sections and mounted on glass slides. Then, the sections were depar-
affinized with xylene, counterstained with periodic acid-Schiff (PAS),
and examined under a light microscope (200 magnification, Dialux
22; Leitz, Milan, Italy). We evaluated the loss of the brush-border
membrane, vacuolation, and desquamation of epithelial cells in renal
tubules beginning 24 h after cisplatin treatment. A renal pathologist
blinded to the study groups examined five different fields of the outer
medullary area in every slide. The magnitude of the damage to the
tubular epithelial cells was determined in PAS-stained sections by
counting the numbers of tubules injured in the outer medulla.
RNA Extraction, Semiquantitative RT-PCR, and Real-Time PCR
Total RNA was extracted from kidney sections stored at 70°C
using an RNeasy Mini Kit (Qiagen, Hilden, Germany). cDNA was
synthesized from 1 g of total RNA using an oligo dT primer
(Amersham Pharmacia, Piscataway, NJ), dNTPs (Amersham Pharma-
cia), Moloney murine leukemia virus reverse transcriptase (GIBCO-
BRL, Grand Island, NY), 0.1 M DTT, and buffer in a volume of 20
l. Then, the 20 l of cDNA were diluted to a total volume of 100 l.
Using SYBR Green PCR Master Mix (Applied Biosystems, Foster
City, CA), PCR was used to amplify cDNA for iNOS [primers
5-TCC CAG ACC CCA TAA CAA CAG-3 (sense) and 5-TGA
GGG TGC AGC GAA CTT TA-3 (antisense)], eNOS [5-TCC CAG
ACC CCA TAA CAA CAG-3 (sense) and 5-TGA GGG TGC AGC
Fig. 1. Diagram of the study design. In study
1, the rats were divided into sham-operated
rats (S), sildenafil-treated sham-operated rats
(S-Sild), vehicle-treated ischemia-reperfusion
rats (IR), and sildenafil-treated ischemia-
reperfusion rats (IR-Sild). The rats were sub-
jected to a right nephrectomy followed by 35
min of ischemia and reperfusion of the left
kidney. After reperfusion of the ischemic left
kidney, blood was sampled at several time
points and the rats were killed. Age- and time-
matched sham-operated control rats were ob-
served in parallel. In study 2, the rats were
divided into sildenafil-treated ischemia-reperfu-
sion (IR-Sild) and sildenafilPD98059-treated
ischemia-reperfusion (IR-Sild-PD) groups. Blood
was sampled, and rats were killed 24 h after
reperfusion of the ischemic left kidney.
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GAA CTT TA-3 (antisense)], and GAPDH [5-TCC CAG ACC CCA
TAA CAA CAG-3 (sense) and 5-TGA GGG TGC AGC GAA CTT
TA-3 (antisense)]. The amplification reaction volume was 20 l,
which consisted of 10 l iQ SYBR Green PCR Master Mix, 1 l
primers, 1 l cDNA, and 8 l H2O. Amplification and detection were
performed using a thermal cycler (Rotor-Gene 6000; Corbett Research,
Mortlake, NSW, Australia). The PCR conditions consisted of denatur-
ation at 95°C for 10 min, followed by 40 cycles consisting of 10 s at
95°C, 15 s at 60°C, and 20 s at 72°C. The fluorescence of SYBR green
was measured at the end of each cycle using the comparative threshold
cycle (Ct) method. The cDNA was quantified using the following
formula
2Ct
 2	Ct of target geneCt of GAPDH in treated rats
	Ct of target geneCt of GAPDH in sham rats

Western Blotting
Kidney sections stored at 70°C were homogenized in protein ex-
traction solution (PRO-PREP; iNtRON, Sungnam-si, Korea). The ho-
mogenates were centrifuged (12,000 g, 15 min, 4°C), and the protein
concentrations in the supernatant were determined using the Bradford
method (Bio-Rad, Hercules, CA). The centrifuged proteins were
mixed with the same volume of 2 SDS sample buffer [62.5 mM,
Tris HCl (pH 6.8), 6% (wt/vol) SDS, 30% glycerol, 125 mM DTT,
and 0.3% (wt/vol) bromophenol blue], so that the ultimate concentra-
tion of the mixture was 1 (500 g/100 l). The homogenates were
heated at 94°C for 5 min in Laemmli sample buffer. Then, 40 g of
total protein were loaded in a stacking polyacrylamide gel and
resolved on 8 and 15% polyacrylamide gels with a standard biotinyl-
ated molecular weight marker. The samples were wet-transferred to a
0.2-m nitrocellulose membrane (Amersham Pharmacia), which was
stained with Coomassie blue to assess equal loading of protein.
Subsequently, the blots were blocked for 1 h with 5% nonfat dry milk
in TBST buffer (20 mM Tris HCl, pH 7.6, 0.8% NaCl, and 0.05%
Tween 20) and incubated overnight at 4°C with 1:1,000 cleaved/total
caspase-3 antibody, ERK/pERK, and Bcl-2 (Cell Signaling Technol-
ogy, Beverly, MA), and 1:1,000 iNOS, eNOS, Bax, and -actin
antibody (Santa Cruz Biotechnology, Santa Cruz, CA). After washing
in TBST, the blots were incubated with 1:1,000 secondary anti-rabbit
or anti-goat IgG-HRP-linked antibody (Cell Signaling Technology)
for 1 h. The blots were washed again in TBST, and the bands were
detected using enhanced chemiluminescence (Millipore, Billerica,
MA) and exposed to film. The optical density for quantification was
obtained with Gel-Pro Analyzer version 3.1 (Media Cybernetics,
Silver Spring, MD).
cGMP Measurement
Outer medullary area tissue lysate (50 mg) was used. The tissues
were chopped and incubated in cell lysis buffer (R&D Systems,
Minneapolis, MN). Then, the cells were frozen at 20°C and thawed
with gentle mixing. The freeze/thaw cycle was repeated twice. The
mixture was centrifuged (600 g, 10 min, 4°C) to remove cellular
debris. The supernatant was aliquoted and stored at 20°C for cGMP
determination. cGMP levels were assayed in duplicate using an
ELISA kit (R&D Systems, Minneapolis, MN). A set of standards
(2.1–500 pmol/ml) was assayed in duplicate with the samples. Non-
specific binding and background signals were subtracted from each
reading, and the average optical density was calculated. Values are
presented as picomoles of cGMP per milligram protein.
Caspase-3 Activity Assay
Caspase-3 activities in the lysates were determined using a Chemi-
con caspase colorimetric activity assay kit (Chemicon, Temecula,
CA). The tissues were chopped and incubated in cell lysis buffer for
10 min. After centrifugation (5 min, 10,000 g), the supernatant was
aliquoted and analyzed immediately, according to the manufacturer’s
protocol. The assay is based on the spectrophotometric detection of
the chromophore p-nitroaniline (pNA) after cleavage from the labeled
substrate LEHD-pNA. Free pNA can be quantified using a microtiter
plate reader at 405 nm. The fold-increase in caspase-3 activity was
determined by comparing optical density readings from the S-Sild, IR,
and IR-Sild groups to those of the S group in study 1, and by
comparing optical density readings from the IR-Sild-PD group to
those of the IR-Sild group in study 2.
TUNEL
TUNEL was performed in situ using an Apoptosis Detection Kit
(S7100-KIT; Chemicon). The procedure was modified from the man-
ufacturer-recommended protocol. First, the 4-m-thick paraffin-em-
bedded sections were dewaxed in three changes of xylene for 10 min
each. These were rehydrated in a graded series of alcohol from
absolute, to 95, 80, and 70%, to water. After rinsing in PBS for 5 min,
the sections were incubated in 0.3% H2O2 at room temperature to
eliminate endogenous peroxidase activity. Then, the sections were
washed in two changes of distilled water for 5 min each, followed by
PBS for another 5 min. Proteinase K (10 g/ml in 0.1 M Tris, 50 mM
EDTA, pH 8) was applied on the sections, which were incubated for
15 min at room temperature. After the sections were washed in four
changes of distilled water for 2 min each, and one change of PBS for 5
min, two drops of equilibration buffer were applied to the sections for 0.5
to 1 min to facilitate the penetration of terminal dUTP transferase, the
TdT enzyme. A reaction mixture was prepared by mixing the reaction
buffer and TdT enzyme in a ratio of 5:1. Then, this reaction mixture was
applied to the sections, which were incubated in a humidified chamber for
1 h at 37°C to allow extension of the nick ends of the DNA fragments
with digoxigenin-dUTP. During the incubation process, coverslips were
put on the sections to prevent them from drying out. After incubation,
the coverslips were removed carefully, without disturbing the tissues,
and the sections were washed in a stop buffer (1 ml of stock in the kit
and 34 ml of distilled water) for 30 min at 37°C. After the sections
were washed in PBS for 5 min, two drops of peroxidase-conjugated
anti-DIG antibody were applied for 30 min at room temperature. After
rinsing of the sections in three changes of PBS followed by one
change in Tris buffer, color was developed using 0.05% diaminoben-
zidine (DAB) with 0.006% H2O2 as a substrate. Finally, the sections
were washed in water, counterstained with methyl green, dehydrated
through a graded alcohol series, cleared in xylene, and mounted with
Permount for light microscopic observation. For negative controls,
distilled water was used instead of TdT enzyme.
Statistical Analysis
The data are reported as the means  SD. Multiple comparisons
among groups were performed using the t-test and ANOVA with the
post hoc Bonferroni test correction (SPSS 11.0 for Windows; SPSS,
Chicago, IL). The difference among groups was considered statisti-
cally significant at P  0.05.
RESULTS
Effects of Sildenafil on Renal Function and Histology
BUN levels were significantly elevated in the vehicle-treated
IR group at 24, 48, and 72 h after reperfusion, compared with
time-matched sham-operated rats. In contrast, intraperitoneal
injection of sildenafil reduced BUN levels compared with
vehicle-treated IR rats at 24, 48, and 72 h after reperfusion.
Serum creatinine levels were also significantly elevated in the
vehicle-treated IR group at 24 and 48 h after reperfusion,
compared with time-matched sham-operated rats, whereas sil-
denafil treatment reduced serum creatinine levels, compared
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with vehicle-treated IR rats, at 24 and 48 h after reperfusion
(P  0.05, Fig. 2).
Histological examination revealed loss of the brush border,
vacuolation, and desquamation of epithelial cells in renal
tubular epithelium in rats 24 h after vehicle-treated IR, whereas
pretreatment with sildenafil attenuated the renal tubular injuries
(P  0.05, Fig. 3).
Antiapoptotic Effects of Sildenafil
Expression of Bcl-2/Bax. Bcl-2 and Bax expression were
measured in kidney samples 24 h after reperfusion in vehicle-
and sildenafil-treated IR rats. Protein was extracted, and Bcl-2,
Bax, and -actin were identified using Western blotting. The
expression of Bcl-2 and Bax was normalized against -actin
expression. The level of Bax was elevated in the kidneys of IR
rats compared with the kidneys of the sham rats and rats treated
only with sildenafil (P  0.05). Pretreatment with sildenafil
prevented the elevation of Bax in the kidneys of IR rats. No
difference was observed in Bcl-2 levels between sildenafil- and
vehicle-treated IR rats. However, the Bax/Bcl-2 ratio was
elevated in the kidneys of IR rats compared with the kidneys of
the sham and sildenafil-only rats (P  0.05). The ratio of Bax
to Bcl-2 was calculated as an index of apoptotic signaling.
Pretreatment with sildenafil prevented the elevation of the
Bax/Bcl-2 ratio in the kidneys of IR rats (P  0.05, Fig. 4).
Caspase-3 activity assay. Caspase-3 activity increased sig-
nificantly in the kidneys of IR rats compared with those of the
sham and sildenafil-only rats (P  0.05). Sildenafil adminis-
tration reduced caspase-3 activity in IR rats (P  0.05, Fig. 4).
TUNEL. The number of TUNEL-positive cells increased in
the kidneys of IR rats compared with those of the sham and
sildenafil-only rats (P  0.01). Sildenafil administration pre-
vented the increase in the number of TUNEL-positive cells
(P  0.05, Fig. 5).
Expression of cGMP and eNOS/iNOS
cGMP accumulation was measured in kidney samples at
4.58 and 24.58 h in sham-operated and sildenafil-pretreated
sham-operated rats, and at 4 and 24 h after reperfusion in IR
rats. cGMP accumulation increased significantly in the kidney
in the sildenafil-treated IR group, compared with the vehicle-
treated IR group at 4 and 24 h after reperfusion.
eNOS and iNOS expression was measured in kidney samples
at 1, 2, 4, and 24 h after reperfusion in vehicle- and sildenafil-
treated IR rats. iNOS mRNA expression peaked at 2 h in both
the vehicle- and sildenafil-treated IR groups, and no difference
was found between these two groups. eNOS mRNA expression
peaked at 4 h in both groups, but the increase was greater in the
sildenafil-treated IR group than in the vehicle-treated IR group
(P  0.05). Regarding the levels of proteins, eNOS was
Fig. 2. Effects of sildenafil on renal function show-
ing the temporal changes in serum blood urea nitro-
gen (BUN) and creatinine. Group definitions are the
same as for Fig. 1. *P  0.01 vs. sham group. #P 
0.05 vs. vehicle-treated IR group.
Fig. 3. Effects of sildenafil on renal histology
(original magnification 200). A: changes in
renal histology 24 h after renal IR injury. The
vehicle-treated IR kidneys showed marked in-
jury, with sloughing of tubular epithelial cells
and loss of the brush border. These changes
were reduced by sildenafil treatment. B: per-
centage of damaged tubules. *P  0.01 vs.
sham group. #P  0.05 vs. vehicle-treated IR
group.
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elevated in the kidneys of sildenafil-treated IR rats compared
with those of the vehicle-treated IR group 4 and 24 h after
reperfusion. iNOS was elevated 24 h after reperfusion in the
sildenafil-treated IR group compared with the vehicle-treated
IR group (P  0.05, Fig. 6).
ERK Phosphorylation and Kidney Injury
ERK expression was measured in kidney samples at 2, 4,
and 24 h after reperfusion in vehicle- and sildenafil-treated IR
rats. The increased ERK phosphorylation was prolonged in the
Fig. 4. A: densitometric analysis of Bax and
Bcl-2 immunoblots. Sildenafil pretreatment
decreased the Bax/Bcl-2 ratio in IR. B: rep-
resentative photomicrographs of Bax and
Bcl-2 immunostaining in vehicle-treated IR
group. C: colorimetric analysis of caspase-3
activity. Sildenafil pretreatment suppressed
caspase-3 activity at 4 and 24 h after reper-
fusion. *P  0.05 vs. sham group. #P  0.05
vs. vehicle-treated IR group.
Fig. 5. A: representative photomicrographs of
terminal dUTP nick end-labeling (TUNEL;
original magnification 400). Vehicle-treated
IR kidneys contained more TUNEL-positive
cells. Sildenafil pretreatment reduced the num-
ber of TUNEL-positive cells. B: quantitative
analysis of TUNEL-positive cells. *P 0.01 vs.
sham group. #P  0.05 vs. vehicle-treated IR
group.
F366 SILDENAFIL ATTENUATES IR RENAL INJURY
AJP-Renal Physiol • VOL 297 • AUGUST 2009 • www.ajprenal.org
Fig. 6. Renal expression of cGMP, inducible nitric
oxide synthase (iNOS), and endothelial nitric oxide
synthase (eNOS). A: cGMP accumulation in the
outer medullary area tissue isolated from rats. Sil-
denafil pretreatment resulted in increased cGMP
levels in IR rats. B: temporal analysis of iNOS and
eNOS using semiquantitative RT-PCR and real-time
PCR. C-a: densitometric analysis of iNOS and
eNOS immunoblots. Sildenafil pretreatment resulted
in increased iNOS and eNOS. C-b: representative
photomicrographs of immunostaining for iNOS and
eNOS. *P  0.05 vs. sham group. #P  0.05 vs.
vehicle-treated IR group.
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sildenafil-treated IR group compared with the vehicle-treated
IR group. PD98059 pretreatment of sildenafil-treated IR rats
significantly reduced the phosphorylation of ERK, increased
BUN and serum creatinine, decreased eNOS and iNOS pro-
duction, increased Bax/Bcl-2 ratio, and increased caspase ac-
tivity. By contrast, the accumulation of cGMP was not affected
by PD98059 pretreatment of sildenafil-treated IR rats. (P 
0.05, Fig. 7).
DISCUSSION
In this study, we demonstrated that sildenafil has renopro-
tective effects against renal IR injury, attenuating the renal
tubular damage, decreasing apoptosis, and suppressing the
increases in the BUN and serum creatinine. This protection is due
primarily to the inhibition of apoptosis and necrosis, as clearly
revealed by our finding that pretreatment with sildenafil increased
iNOS/eNOS and decreased the activation of caspase-3, TUNEL-
positive cells, and the Bax/Bcl-2 ratio.
Apoptosis is one of the important mechanisms of cell death
in cultured renal tubular cells and isolated kidneys following
renal IR injury. Apoptosis is associated with the upregulation
of proapoptotic protein (Bax), downregulation of antiapoptotic
protein (Bcl-2), and increased caspase-3 activity (33, 34, 42).
We observed a significant increase in Bcl-2 and decreases in
Bax and cleaved caspase-3 in the sildenafil-treated IR rats
compared with the vehicle-treated IR rats, demonstrating the
antiapoptotic capacity of sildenafil in renal IR injury. Further-
more, the number of TUNEL-positive cells was significantly
Fig. 7. A: representative photomicrographs of immunostaining for ERK in kidney samples at 2, 4, and 24 h after reperfusion in vehicle- and sildenafil-treated
IR rats. Sildenafil pretreatment prolonged the increase in ERK phosphorylation at 4 and 24 h after reperfusion in IR rats. B: BUN and serum creatinine levels.
C-a: densitometric analysis of ERK, eNOS, iNOS, Bax, and Bcl-2 immunoblots. PD98059 pretreatment increased the Bax/Bcl-2 ratio and decreased eNOS and
iNOS levels after sildenafil-treated IR. C-b: representative photomicrographs of ERK, eNOS, 55 iNOS, Bax, and Bcl-2 immunostaining. D: colorimetric analysis
of caspase-3 activity. PD98059 pretreatment increased caspase-3 activity 24 h after reperfusion in sildenafil-treated IR rats. E: cGMP accumulation in the outer
medullary area tissue isolated from rats. PD98059 pretreatment did not decrease cGMP accumulation in sildenafil-treated IR rats. *P  0.05 vs. sildenafil-treated
IR group. #P  0.05 vs. vehicle-treated IR group.
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lower in the kidneys from sildenafil-treated IR rats compared
with the vehicle-treated IR rats.
The ERK cascade mediates cell growth and survival signals
in many cell types, and ERK activation protects renal epithelial
cells from oxidative injury (21). Sildenafil induces ERK acti-
vation (24), although the exact mechanism of the sildenafil-
mediated enhancement of ERK activity is not known. Our
results also demonstrated that sildenafil significantly enhanced
ERK activation, compared with the vehicle-treated IR rats.
PD98059 attenuated the sildenafil-induced increase in ERK
phosphorylation and also diminished the sildenafil-induced
renoprotective effect in IR injury.
Many studies have documented an interaction between NO
and ERK. However, the detailed mechanism explaining the
interaction between these molecules in either direction has not
been fully elucidated. It has been reported that the activation of
ERK by sildenafil leads to increased NOS activity and subse-
quent rapid NO release (47). In cardiac tissue, NO enhances the
formation of cGMP, which activates PKG (30). It has also been
reported that NO release is mediated by NOS-induced phos-
phorylation and activation of ERK1/2 in isolated rat cardio-
myocytes and the intact heart, suggesting that ERK activation
is downstream of NOS (43). Our data showed that PD98059
did not diminish the sildenafil-induced accumulation of cGMP,
although it did diminish the expression of cytoprotective pro-
teins, including iNOS, eNOS, and Bcl-2. To our knowledge,
there is no report on the time course of sildenafil-induced ERK
phosphorylation. Das et al. (9, 11) reported that ERK plays an
important role in both the early and delayed phases of silde-
nafil-induced cardioprotection against IR injury in mice. How-
ever, our data showed no difference in ERK phosphorylation
between the IR and IR-Sild groups at 2 h after reperfusion, but
there was a difference at 4 and 24 h after reperfusion. Our
results show that ERK phosphorylation occurs downstream of
cGMP production within a sildenafil-induced signaling cas-
cade.
Sildenafil, a PDE-5 inhibitor, prevents the breakdown of
NO-driven cGMP, primarily in vascular smooth muscle cells,
and is therefore a potent vasodilator (2). In renal IR injury,
endogenous NO is synthesized by eNOS and iNOS (40). Many
studies have confirmed that eNOS-mediated NO production
plays a pivotal protective role in IR-induced acute renal failure
(18, 44, 45). However, the role of iNOS in renal IR remains
controversial. Some studies have demonstrated that renal IR
injury was efficiently attenuated by a genetic deficiency or the
pharmacological blockade of iNOS (3, 12, 25, 41), while other
recent studies clearly demonstrated that iNOS-generated NO
inhibited IR-induced renal damage (31, 38). This difference
may be due to the different levels of NO production associated
with the degree or method of IR injury. We demonstrated that
sildenafil significantly enhanced iNOS and eNOS in the silde-
nafil-treated IR rats compared with the vehicle-treated IR rats.
However, Elrod et al. (13) reported that sildenafil has a pro-
tective effect, independent of the NO/cGMP pathway (i.e.,
independent of iNOS, eNOS, and cGMP levels) in a model
using 30 min of ischemia and 24 h of reperfusion. This means
that other protective pathways involving sildenafil exist, so that
further studies are needed.
In conclusion, this study revealed that sildenafil improved
the recovery of renal injury during IR by enhancing the
activation of ERK, induction of iNOS and eNOS production,
and decreasing the Bax/Bcl-2 ratio. The ability of sildenafil to
induce ischemic tolerance suggests that there are advantages in
its application in kidney transplantation. Clinical studies are
necessary to evaluate the therapeutic properties of sildenafil in
preventing IR injury.
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